Zyvox - linezolid + Matched control
Phase 3Terminated 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Optic Nerve Diseases
Conditions
Optic Nerve Diseases
Trial Timeline
Nov 1, 2008 → Dec 1, 2013
NCT ID
NCT00359632About Zyvox - linezolid + Matched control
Zyvox - linezolid + Matched control is a phase 3 stage product being developed by Pfizer for Optic Nerve Diseases. The current trial status is terminated. This product is registered under clinical trial identifier NCT00359632. Target conditions include Optic Nerve Diseases.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00359632 | Phase 3 | Terminated |
Competing Products
20 competing products in Optic Nerve Diseases
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Satralizumab 120 mg | Chugai Pharmaceutical | Approved | 85 |
| Satralizumab + Placebo + Baseline Treatment | Chugai Pharmaceutical | Phase 3 | 77 |
| Satralizumab + Placebo | Chugai Pharmaceutical | Phase 3 | 77 |
| PDE5 Inhibitors | Eli Lilly | Pre-clinical | 23 |
| Atacicept + Placebo matched to atacicept | Merck | Phase 2 | 52 |
| Fingolimod 0.5mg/daily + Placebo | Novartis | Phase 2 | 52 |
| satralizumab + azathioprine (AZA) + mycophenolate mofetil (MMF) + oral corticosteroids | Roche | Phase 3 | 77 |
| Satralizumab | Roche | Phase 3 | 77 |
| UPLIZNA | Amgen | Pre-clinical | 22 |
| Inebilizumab | Amgen | Phase 2 | 51 |
| Inebilizumab | Amgen | Approved | 84 |
| Dexmedetomidine HCL Injection + Placebo | Pfizer | Phase 3 | 76 |
| No intervention | Pfizer | Pre-clinical | 22 |
| Efgartigimod Alfa + Placebo | Argenx | Phase 2 | 49 |
| Diagnostic procedures | Bayer | Approved | 82 |
| Placebo + BIIB033 100mg/Kg | Biogen | Phase 2 | 49 |
| BIIB033 (anti-LINGO-1 mAb) + Placebo | Biogen | Phase 2 | 49 |
| intravenous methylprednisolone | Brain Biotech | Pre-clinical | 15 |
| OCS-05 +SoC (corticosteroid) IV administration | Oculis Holding AG | Phase 2 | 47 |
| EVO756 + EVO756 + EVO756 + Placebo control | Evommune | Phase 2 | 47 |